{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T14:43:23Z","timestamp":1786200203488,"version":"build-2736575974"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40263-024-01098-9","type":"journal-article","created":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T22:02:01Z","timestamp":1719871321000},"page":"597-612","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The State of Synthetic Cannabinoid Medications for the Treatment of Pain"],"prefix":"10.1007","volume":"38","author":[{"given":"Anca","family":"Maglaviceanu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Peer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Rockel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Bonin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary-Ann","family":"Fitzcharles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim S.","family":"Ladha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Leroux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Kotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohit","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4975-3823","authenticated-orcid":false,"given":"Hance","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,1]]},"reference":[{"issue":"1","key":"1098_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1089\/can.2016.0027","volume":"1","author":"A Pollio","year":"2016","unstructured":"Pollio A. The name of cannabis: a short guide for nonbotanists. Cannabis Cannabinoid Res. 2016;1(1):234\u20138.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"5","key":"1098_CR2","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/10408444.2020.1762539","volume":"50","author":"VL Alves","year":"2020","unstructured":"Alves VL, et al. The synthetic cannabinoids phenomenon: from structure to toxicological properties. A review. Crit Rev Toxicol. 2020;50(5):359\u201382.","journal-title":"Crit Rev Toxicol"},{"issue":"2","key":"1098_CR3","first-page":"153","volume":"30","author":"Z Mouslech","year":"2009","unstructured":"Mouslech Z, Valla V. Endocannabinoid system: an overview of its potential in current medical practice. Neuro Endocrinol Lett. 2009;30(2):153\u201379.","journal-title":"Neuro Endocrinol Lett"},{"issue":"1","key":"1098_CR4","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/npp.2017.130","volume":"43","author":"CJ Hillard","year":"2018","unstructured":"Hillard CJ. Circulating endocannabinoids: from whence do they come and where are they going? Neuropsychopharmacology. 2018;43(1):155\u201372.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1098_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1089\/can.2016.0004","volume":"1","author":"V Shevyrin","year":"2016","unstructured":"Shevyrin V, et al. On a new cannabinoid classification system: a sight on the illegal market of novel psychoactive substances. Cannabis Cannabinoid Res. 2016;1(1):186\u201394.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"9","key":"1098_CR6","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nrd.2018.115","volume":"17","author":"V Di Marzo","year":"2018","unstructured":"Di Marzo V. New approaches and challenges to targeting the endocannabinoid system. Nat Rev Drug Discov. 2018;17(9):623\u201339.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"1098_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.31887\/DCNS.2020.22.3\/vdimarzo","volume":"22","author":"V Di Marzo","year":"2020","unstructured":"Di Marzo V. The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders. Dialogues Clin Neurosci. 2020;22(3):259\u201369.","journal-title":"Dialogues Clin Neurosci"},{"issue":"4","key":"1098_CR8","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"RG Pertwee","year":"2010","unstructured":"Pertwee RG, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB\u2081 and CB\u2082. Pharmacol Rev. 2010;62(4):588\u2013631.","journal-title":"Pharmacol Rev"},{"issue":"Suppl 2","key":"1098_CR9","first-page":"S37","volume":"61","author":"JD Brown","year":"2021","unstructured":"Brown JD, et al. Natural and synthetic cannabinoids: pharmacology, uses, adverse drug events, and drug interactions. J Clin Pharmacol. 2021;61(Suppl 2):S37\u201352.","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"1098_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1089\/can.2017.0036","volume":"2","author":"P Morales","year":"2017","unstructured":"Morales P, Reggio PH. An update on non-CB(1), non-CB(2) cannabinoid related g-protein-coupled receptors. Cannabis Cannabinoid Res. 2017;2(1):265\u201373.","journal-title":"Cannabis Cannabinoid Res"},{"key":"1098_CR11","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.3389\/fphar.2018.01259","volume":"9","author":"S Vu\u010dkovi\u0107","year":"2018","unstructured":"Vu\u010dkovi\u0107 S, et al. Cannabinoids and pain: new insights from old molecules. Front Pharmacol. 2018;9:1259.","journal-title":"Front Pharmacol"},{"key":"1098_CR12","doi-asserted-by":"publisher","first-page":"1041833","DOI":"10.3389\/fphys.2022.1041833","volume":"13","author":"M Oz","year":"2022","unstructured":"Oz M, Yang KS, Mahgoub MO. Effects of cannabinoids on ligand-gated ion channels. Front Physiol. 2022;13:1041833.","journal-title":"Front Physiol"},{"issue":"3","key":"1098_CR13","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/ijms19030833","volume":"19","author":"S Zou","year":"2018","unstructured":"Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833.","journal-title":"Int J Mol Sci"},{"issue":"14","key":"1098_CR14","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.3390\/ijms21145064","volume":"21","author":"D An","year":"2020","unstructured":"An D, et al. Targeting cannabinoid receptors: current status and prospects of natural products. Int J Mol Sci. 2020;21(14):5064.","journal-title":"Int J Mol Sci"},{"issue":"17","key":"1098_CR15","doi-asserted-by":"publisher","first-page":"9472","DOI":"10.3390\/ijms22179472","volume":"22","author":"H Lowe","year":"2021","unstructured":"Lowe H, et al. The endocannabinoid system: a potential target for the treatment of various diseases. Int J Mol Sci. 2021;22(17):9472.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"1098_CR16","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1089\/can.2016.0020","volume":"1","author":"M Wang","year":"2016","unstructured":"Wang M, et al. Decarboxylation study of acidic cannabinoids: a novel approach using ultra-high-performance supercritical fluid chromatography\/photodiode array-mass spectrometry. Cannabis Cannabinoid Res. 2016;1(1):262\u201371.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"6","key":"1098_CR17","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/2045125312457586","volume":"2","author":"Z Atakan","year":"2012","unstructured":"Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2(6):241\u201354.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"1098_CR18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3390\/antiox9010021","volume":"9","author":"S Atalay","year":"2019","unstructured":"Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and anti-inflammatory properties of cannabidiol. Antioxidants (Basel). 2019;9(1):21.","journal-title":"Antioxidants (Basel)"},{"key":"1098_CR19","unstructured":"U.S. Food & Drug Administration. FDA and cannabis: research and drug approval process. 2023. https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-and-cannabis-research-and-drug-approval-process."},{"issue":"3","key":"1098_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.31887\/DCNS.2020.22.3\/mcrocq","volume":"22","author":"MA Crocq","year":"2020","unstructured":"Crocq MA. History of cannabis and the endocannabinoid system. Dialogues Clin Neurosci. 2020;22(3):223\u20138.","journal-title":"Dialogues Clin Neurosci"},{"key":"1098_CR21","unstructured":"National Library of Medicine. 2023. https:\/\/clinicaltrials.gov\/."},{"issue":"2","key":"1098_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.394","volume":"6","author":"SH Burstein","year":"2018","unstructured":"Burstein SH. Ajulemic acid: potential treatment for chronic inflammation. Pharmacol Res Perspect. 2018;6(2): e00394.","journal-title":"Pharmacol Res Perspect"},{"issue":"11","key":"1098_CR23","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrn3811","volume":"15","author":"R Mechoulam","year":"2014","unstructured":"Mechoulam R, et al. Early phytocannabinoid chemistry to endocannabinoids and beyond. Nat Rev Neurosci. 2014;15(11):757\u201364.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"1098_CR24","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/j.1476-5381.2008.00048.x","volume":"156","author":"RG Pertwee","year":"2009","unstructured":"Pertwee RG. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009;156(3):397\u2013411.","journal-title":"Br J Pharmacol"},{"issue":"12","key":"1098_CR25","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.lfs.2004.10.025","volume":"76","author":"RG Pertwee","year":"2005","unstructured":"Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci. 2005;76(12):1307\u201324.","journal-title":"Life Sci"},{"issue":"1","key":"1098_CR26","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3390\/medicina56010024","volume":"56","author":"BI Tamba","year":"2020","unstructured":"Tamba BI, et al. Challenges and opportunities in preclinical research of synthetic cannabinoids for pain therapy. Medicina (Kaunas). 2020;56(1):24.","journal-title":"Medicina (Kaunas)"},{"issue":"14","key":"1098_CR27","doi-asserted-by":"publisher","first-page":"5722","DOI":"10.1021\/jm400305d","volume":"56","author":"SP Hollinshead","year":"2013","unstructured":"Hollinshead SP, et al. Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain. J Med Chem. 2013;56(14):5722\u201333.","journal-title":"J Med Chem"},{"issue":"19\u201320","key":"1098_CR28","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1016\/j.lfs.2008.09.004","volume":"83","author":"JA Stebulis","year":"2008","unstructured":"Stebulis JA, et al. Ajulemic acid, a synthetic cannabinoid acid, induces an antiinflammatory profile of eicosanoids in human synovial cells. Life Sci. 2008;83(19\u201320):666\u201370.","journal-title":"Life Sci"},{"key":"1098_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.172628","volume":"862","author":"VS Kumawat","year":"2019","unstructured":"Kumawat VS, Kaur G. Therapeutic potential of cannabinoid receptor 2 in the treatment of diabetes mellitus and its complications. Eur J Pharmacol. 2019;862: 172628.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"1098_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.bja.2020.09.026","volume":"126","author":"KS Ladha","year":"2021","unstructured":"Ladha KS, et al. Perioperative Pain and Addiction Interdisciplinary Network (PAIN): consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users by a modified Delphi process. Br J Anaesth. 2021;126(1):304\u201318.","journal-title":"Br J Anaesth"},{"issue":"3","key":"1098_CR31","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/rapm-2022-104013","volume":"48","author":"S Shah","year":"2023","unstructured":"Shah S, et al. ASRA Pain Medicine consensus guidelines on the management of the perioperative patient on cannabis and cannabinoids. Reg Anesth Pain Med. 2023;48(3):97\u2013117.","journal-title":"Reg Anesth Pain Med"},{"issue":"1","key":"1098_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.lfs.2013.09.011","volume":"97","author":"JL Wiley","year":"2014","unstructured":"Wiley JL, Marusich JA, Huffman JW. Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids. Life Sci. 2014;97(1):55\u201363.","journal-title":"Life Sci"},{"issue":"3","key":"1098_CR33","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1476-5381.2009.00582.x","volume":"160","author":"BK Atwood","year":"2010","unstructured":"Atwood BK, et al. JWH018, a common constituent of \u201cSpice\u201d herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol. 2010;160(3):585\u201393.","journal-title":"Br J Pharmacol"},{"issue":"Suppl 1","key":"1098_CR34","first-page":"S163","volume":"147","author":"RG Pertwee","year":"2006","unstructured":"Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol. 2006;147(Suppl 1):S163\u201371.","journal-title":"Br J Pharmacol"},{"issue":"11","key":"1098_CR35","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"CJ Lucas","year":"2018","unstructured":"Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol. 2018;84(11):2477\u201382.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1098_CR36","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/sj.bjp.0703245","volume":"129","author":"RG Pertwee","year":"2000","unstructured":"Pertwee RG, et al. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br J Pharmacol. 2000;129(8):1577\u201384.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"1098_CR37","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1167\/iovs.16-20757","volume":"58","author":"GR Adelli","year":"2017","unstructured":"Adelli GR, et al. Development of a \u03949-tetrahydrocannabinol amino acid-dicarboxylate prodrug with improved ocular bioavailability. Investig Ophthalmol Vis Sci. 2017;58(4):2167\u201379.","journal-title":"Investig Ophthalmol Vis Sci"},{"issue":"9","key":"1098_CR38","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.3109\/03639041003657295","volume":"36","author":"KS Paudel","year":"2010","unstructured":"Paudel KS, et al. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm. 2010;36(9):1088\u201397.","journal-title":"Drug Dev Ind Pharm"},{"issue":"7","key":"1098_CR39","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1038\/s41386-022-01322-4","volume":"47","author":"S Nielsen","year":"2022","unstructured":"Nielsen S, et al. Opioid-sparing effect of cannabinoids for analgesia: an updated systematic review and meta-analysis of preclinical and clinical studies. Neuropsychopharmacology. 2022;47(7):1315\u201330.","journal-title":"Neuropsychopharmacology"},{"issue":"11","key":"1098_CR40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/j.lfs.2003.09.038","volume":"74","author":"DL Cichewicz","year":"2004","unstructured":"Cichewicz DL. Synergistic interactions between cannabinoid and opioid analgesics. Life Sci. 2004;74(11):1317\u201324.","journal-title":"Life Sci"},{"issue":"16","key":"1098_CR41","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1021\/jm070317a","volume":"50","author":"EK Dziadulewicz","year":"2007","unstructured":"Dziadulewicz EK, et al. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1\/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration. J Med Chem. 2007;50(16):3851\u20136.","journal-title":"J Med Chem"},{"issue":"11","key":"1098_CR42","first-page":"1247","volume":"25","author":"A Lodola","year":"2015","unstructured":"Lodola A, et al. Fatty acid amide hydrolase inhibitors: a patent review (2009\u20132014). Expert Opin Ther Pat. 2015;25(11):1247\u201366.","journal-title":"Expert Opin Ther Pat"},{"issue":"9","key":"1098_CR43","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.pain.2012.04.020","volume":"153","author":"JP Huggins","year":"2012","unstructured":"Huggins JP, et al. An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain. 2012;153(9):1837\u201346.","journal-title":"Pain"},{"issue":"19","key":"1098_CR44","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/cmdc.201800397","volume":"13","author":"M Brindisi","year":"2018","unstructured":"Brindisi M, et al. Development of potent inhibitors of fatty acid amide hydrolase useful for the treatment of neuropathic pain. ChemMedChem. 2018;13(19):2090\u2013103.","journal-title":"ChemMedChem"},{"issue":"8","key":"1098_CR45","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.3390\/ijms23084407","volume":"23","author":"A Della Pietra","year":"2022","unstructured":"Della Pietra A, Savinainen J, Giniatullin R. Inhibiting endocannabinoid hydrolysis as emerging analgesic strategy targeting a spectrum of ion channels implicated in migraine pain. Int J Mol Sci. 2022;23(8):4407.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"1098_CR46","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1021\/acschemneuro.1c00192","volume":"12","author":"A Grillo","year":"2021","unstructured":"Grillo A, et al. Selective fatty acid amide hydrolase inhibitors as potential novel antiepileptic agents. ACS Chem Neurosci. 2021;12(9):1716\u201336.","journal-title":"ACS Chem Neurosci"},{"issue":"3","key":"1098_CR47","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/cells11030471","volume":"11","author":"A Papa","year":"2022","unstructured":"Papa A, et al. Polypharmacological approaches for CNS diseases: focus on endocannabinoid degradation inhibition. Cells. 2022;11(3):471.","journal-title":"Cells"},{"issue":"2","key":"1098_CR48","doi-asserted-by":"publisher","first-page":"122","DOI":"10.2174\/1574889810999160603185126","volume":"10","author":"A Chicca","year":"2016","unstructured":"Chicca A, Arena C, Manera C. Beyond the direct activation of cannabinoid receptors: new strategies to modulate the endocannabinoid system in CNS-related diseases. Recent Pat CNS Drug Discov. 2016;10(2):122\u201341.","journal-title":"Recent Pat CNS Drug Discov"},{"issue":"3","key":"1098_CR49","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/med.21418","volume":"37","author":"T Nguyen","year":"2017","unstructured":"Nguyen T, et al. Allosteric modulation: an alternate approach targeting the cannabinoid CB1 receptor. Med Res Rev. 2017;37(3):441\u201374.","journal-title":"Med Res Rev"},{"issue":"1","key":"1098_CR50","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1365-2133.2012.11177.x","volume":"168","author":"SH Wu","year":"2013","unstructured":"Wu SH, et al. Efficacy and safety of 15(R\/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema. Br J Dermatol. 2013;168(1):172\u20138.","journal-title":"Br J Dermatol"},{"issue":"3","key":"1098_CR51","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/s41401-018-0164-x","volume":"40","author":"D Lu","year":"2019","unstructured":"Lu D, et al. Translational potential of allosteric modulators targeting the cannabinoid CB(1) receptor. Acta Pharmacol Sin. 2019;40(3):324\u201335.","journal-title":"Acta Pharmacol Sin"},{"key":"1098_CR52","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1146\/annurev-pharmtox-031122-113758","volume":"63","author":"R Roque-Bravo","year":"2023","unstructured":"Roque-Bravo R, et al. Synthetic cannabinoids: a pharmacological and toxicological overview. Annu Rev Pharmacol Toxicol. 2023;63:187\u2013209.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"1098_CR53","unstructured":"Sheikh NK, Dua A. Cannabinoids. 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK556062\/."},{"key":"1098_CR54","unstructured":"Ng T, Gupta V, Keshock MC. Tetrahydrocannabinol (THC). 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK563174\/#:~:text=Dronabinol%20and%20nabilone%20are%20contraindicated,alcohol%20in%20the%20oral%20solution."},{"issue":"2","key":"1098_CR55","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0960-894X(95)00573-C","volume":"6","author":"Y Gareau","year":"1996","unstructured":"Gareau Y, et al. Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg Med Chem Lett. 1996;6(2):189\u201394.","journal-title":"Bioorg Med Chem Lett"},{"key":"1098_CR56","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/3-540-26573-2_23","volume":"168","author":"MA Huestis","year":"2005","unstructured":"Huestis MA. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb Exp Pharmacol. 2005;168:657\u201390.","journal-title":"Handb Exp Pharmacol"},{"issue":"1\u20132","key":"1098_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jep.2006.02.001","volume":"105","author":"M Ben Amar","year":"2006","unstructured":"Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105(1\u20132):1\u201325.","journal-title":"J Ethnopharmacol"},{"issue":"4","key":"1098_CR58","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2165\/00003088-200342040-00003","volume":"42","author":"F Grotenhermen","year":"2003","unstructured":"Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327\u201360.","journal-title":"Clin Pharmacokinet"},{"key":"1098_CR59","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0305-7372(82)80031-5","volume":"9 Suppl B","author":"L Lemberger","year":"1982","unstructured":"Lemberger L, et al. Pharmacokinetics, metabolism and drug-abuse potential of nabilone. Cancer Treat Rev. 1982;9 Suppl B:17\u201323.","journal-title":"Cancer Treat Rev"},{"issue":"Suppl A","key":"1098_CR60","doi-asserted-by":"publisher","first-page":"15a","DOI":"10.1155\/2005\/242516","volume":"10","author":"IJ McGilveray","year":"2005","unstructured":"McGilveray IJ. Pharmacokinetics of cannabinoids. Pain Res Manag. 2005;10(Suppl A):15a\u201322a.","journal-title":"Pain Res Manag"},{"issue":"7","key":"1098_CR61","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1093\/jat\/32.7.470","volume":"32","author":"SW Toennes","year":"2008","unstructured":"Toennes SW, et al. Comparison of cannabinoid pharmacokinetic properties in occasional and heavy users smoking a marijuana or placebo joint. J Anal Toxicol. 2008;32(7):470\u20137.","journal-title":"J Anal Toxicol"},{"issue":"23","key":"1098_CR62","doi-asserted-by":"publisher","first-page":"5645","DOI":"10.1523\/JNEUROSCI.0951-05.2005","volume":"25","author":"Z Justinova","year":"2005","unstructured":"Justinova Z, et al. The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys. J Neurosci. 2005;25(23):5645\u201350.","journal-title":"J Neurosci"},{"issue":"1","key":"1098_CR63","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s12916-022-02459-1","volume":"20","author":"A Bilbao","year":"2022","unstructured":"Bilbao A, Spanagel R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 2022;20(1):259.","journal-title":"BMC Med"},{"issue":"7","key":"1098_CR64","doi-asserted-by":"publisher","first-page":"101301","DOI":"10.1016\/j.isci.2020.101301","volume":"23","author":"F Shahbazi","year":"2020","unstructured":"Shahbazi F, et al. Cannabinoids and cannabinoid receptors: the story so far. iScience. 2020;23(7):101301.","journal-title":"iScience"},{"issue":"6284","key":"1098_CR65","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/346561a0","volume":"346","author":"LA Matsuda","year":"1990","unstructured":"Matsuda LA, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990;346(6284):561\u20134.","journal-title":"Nature"},{"issue":"5","key":"1098_CR66","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/WNF.0b013e3181e77428","volume":"33","author":"JA Lile","year":"2010","unstructured":"Lile JA, Kelly TH, Hays LR. Substitution profile of the cannabinoid agonist nabilone in human subjects discriminating \u03b49-tetrahydrocannabinol. Clin Neuropharmacol. 2010;33(5):235\u201342.","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"1098_CR67","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1369-1600.2011.00427.x","volume":"18","author":"G Bedi","year":"2013","unstructured":"Bedi G, Cooper ZD, Haney M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol. 2013;18(5):872\u201381.","journal-title":"Addict Biol"},{"issue":"1","key":"1098_CR68","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","volume":"16","author":"L Cristino","year":"2020","unstructured":"Cristino L, Bisogno T, Di Marzo V. Cannabinoids and the expanded endocannabinoid system in neurological disorders. Nat Rev Neurol. 2020;16(1):9\u201329.","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"1098_CR69","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1021\/acscentsci.1c01100","volume":"8","author":"K Grotsch","year":"2022","unstructured":"Grotsch K, Fokin VV. Between science and big business: tapping Mary Jane\u2019s uncharted potential. ACS Cent Sci. 2022;8(2):156\u201368.","journal-title":"ACS Cent Sci"},{"issue":"7","key":"1098_CR70","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","volume":"152","author":"E Ryberg","year":"2007","unstructured":"Ryberg E, et al. The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007;152(7):1092\u2013101.","journal-title":"Br J Pharmacol"},{"issue":"7","key":"1098_CR71","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/sj.bjp.0707464","volume":"152","author":"RG Pertwee","year":"2007","unstructured":"Pertwee RG. GPR55: a new member of the cannabinoid receptor clan? Br J Pharmacol. 2007;152(7):984\u20136.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"1098_CR72","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1111\/j.1476-5381.2011.01497.x","volume":"165","author":"D McHugh","year":"2012","unstructured":"McHugh D, et al. \u0394(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cells. Br J Pharmacol. 2012;165(8):2414\u201324.","journal-title":"Br J Pharmacol"},{"issue":"8","key":"1098_CR73","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.bbadis.2007.01.008","volume":"1772","author":"JD Levine","year":"2007","unstructured":"Levine JD, Alessandri-Haber N. TRP channels: targets for the relief of pain. Biochim Biophys Acta. 2007;1772(8):989\u20131003.","journal-title":"Biochim Biophys Acta"},{"key":"1098_CR74","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fnmol.2018.00487","volume":"11","author":"C Muller","year":"2018","unstructured":"Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci. 2018;11:487.","journal-title":"Front Mol Neurosci"},{"issue":"1","key":"1098_CR75","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.pharmthera.2007.01.005","volume":"114","author":"K Starowicz","year":"2007","unstructured":"Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther. 2007;114(1):13\u201333.","journal-title":"Pharmacol Ther"},{"issue":"3","key":"1098_CR76","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/sj.bjp.0703850","volume":"132","author":"RA Ross","year":"2001","unstructured":"Ross RA, et al. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol. 2001;132(3):631\u201340.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1098_CR77","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/S0092-8674(02)00637-2","volume":"108","author":"SE Jordt","year":"2002","unstructured":"Jordt SE, Julius D. Molecular basis for species-specific sensitivity to \u201chot\u201d chili peppers. Cell. 2002;108(3):421\u201330.","journal-title":"Cell"},{"issue":"2","key":"1098_CR78","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/sj.bjp.0703050","volume":"129","author":"D Smart","year":"2000","unstructured":"Smart D, et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol. 2000;129(2):227\u201330.","journal-title":"Br J Pharmacol"},{"issue":"24","key":"1098_CR79","doi-asserted-by":"publisher","first-page":"6231","DOI":"10.1523\/JNEUROSCI.0504-08.2008","volume":"28","author":"N Qin","year":"2008","unstructured":"Qin N, et al. TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci. 2008;28(24):6231\u20138.","journal-title":"J Neurosci"},{"issue":"7","key":"1098_CR80","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/j.1476-5381.2010.01166.x","volume":"163","author":"L De Petrocellis","year":"2011","unstructured":"De Petrocellis L, et al. Effects of cannabinoids and cannabinoid-enriched cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol. 2011;163(7):1479\u201394.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1098_CR81","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/j.1748-1716.2011.02338.x","volume":"204","author":"L De Petrocellis","year":"2012","unstructured":"De Petrocellis L, et al. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol (Oxf). 2012;204(2):255\u201366.","journal-title":"Acta Physiol (Oxf)"},{"issue":"12","key":"1098_CR82","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1111\/bph.13497","volume":"173","author":"SE O'Sullivan","year":"2016","unstructured":"O\u2019Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173(12):1899\u2013910.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"1098_CR83","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/gut.2006.093484","volume":"55","author":"L Dubuquoy","year":"2006","unstructured":"Dubuquoy L, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006;55(9):1341\u20139.","journal-title":"Gut"},{"key":"1098_CR84","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/B978-0-12-420126-2.00010-9","volume-title":"The endocannabinoidome","author":"SP Alexander","year":"2015","unstructured":"Alexander SP. Common receptors for endocannabinoid-like mediators and plant cannabinoids. In: The endocannabinoidome. Amsterdam: Elsevier; 2015. p. 153\u201375."},{"issue":"3","key":"1098_CR85","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.bbrc.2005.09.121","volume":"337","author":"SE O'Sullivan","year":"2005","unstructured":"O\u2019Sullivan SE, et al. Novel time-dependent vascular actions of delta9-tetrahydrocannabinol mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun. 2005;337(3):824\u201331.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1098_CR86","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/sj.bjp.0707478","volume":"152","author":"Y Sun","year":"2007","unstructured":"Sun Y, et al. Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism. Br J Pharmacol. 2007;152(5):734\u201343.","journal-title":"Br J Pharmacol"},{"key":"1098_CR87","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.tox.2014.09.011","volume":"326","author":"S Takeda","year":"2014","unstructured":"Takeda S, et al. \u0394(9)-THC modulation of fatty acid 2-hydroxylase (FA2H) gene expression: possible involvement of induced levels of PPAR\u03b1 in MDA-MB-231 breast cancer cells. Toxicology. 2014;326:18\u201324.","journal-title":"Toxicology"},{"issue":"3","key":"1098_CR88","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ejphar.2005.05.032","volume":"517","author":"M Bouaboula","year":"2005","unstructured":"Bouaboula M, et al. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol. 2005;517(3):174\u201381.","journal-title":"Eur J Pharmacol"},{"issue":"10","key":"1098_CR89","doi-asserted-by":"publisher","first-page":"4203","DOI":"10.1038\/s41380-023-02182-0","volume":"28","author":"B Hempel","year":"2023","unstructured":"Hempel B, et al. PPAR\u03b1 and PPAR\u03b3 are expressed in midbrain dopamine neurons and modulate dopamine- and cannabinoid-mediated behavior in mice. Mol Psychiatry. 2023;28(10):4203\u201314.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"1098_CR90","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s40290-022-00447-7","volume":"36","author":"F Modaresi","year":"2022","unstructured":"Modaresi F, Talachian K. The characteristics of clinical trials on cannabis and cannabinoids: a review of trials for therapeutic or drug development purposes. Pharm Med. 2022;36(6):387\u2013400.","journal-title":"Pharm Med"},{"issue":"3","key":"1098_CR91","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/1440-1681.12051","volume":"40","author":"J Kalliom\u00e4ki","year":"2013","unstructured":"Kalliom\u00e4ki J, et al. Evaluation of the analgesic efficacy and psychoactive effects of AZD1940, a novel peripherally acting cannabinoid agonist, in human capsaicin-induced pain and hyperalgesia. Clin Exp Pharmacol Physiol. 2013;40(3):212\u20138.","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"1","key":"1098_CR92","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.sjpain.2012.08.004","volume":"4","author":"J Kalliom\u00e4ki","year":"2013","unstructured":"Kalliom\u00e4ki J, et al. Evaluation of the analgesic efficacy of AZD1940, a novel cannabinoid agonist, on post-operative pain after lower third molar surgical removal. Scand J Pain. 2013;4(1):17\u201322.","journal-title":"Scand J Pain"},{"issue":"13","key":"1098_CR93","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1001\/jama.290.13.1757","volume":"290","author":"M Karst","year":"2003","unstructured":"Karst M, et al. Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: a randomized controlled trial. JAMA. 2003;290(13):1757\u201362.","journal-title":"JAMA"},{"key":"1098_CR94","unstructured":"Mackay M, ZR, Kamen D Koumpouras F, Askanase A, Kalunian K, Schulz S, Franchin G, Olsen N, Coca A, Caricchio R, McMahon M, Dall'Era M, Saxena A, Clowse M, Ballou S, Ding L, Welch B, Springer J, Shaw A, Keyes-Elstein L, Steinmiller K, Mickey A, Aranow C, Diamond B. A phase 2, double-blind, randomized, placebo-controlled multicenter study to evaluate efficacy, safety, and tolerability of JBT-101\/lenabasum in systemic lupus erythematosus, an Autoimmunity Centers of Excellence Study (ALE09) [abstract]. Arthritis Rheumatol. 2022;74."},{"issue":"8","key":"1098_CR95","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1097\/AJP.0b013e318219799a","volume":"27","author":"T Ostenfeld","year":"2011","unstructured":"Ostenfeld T, et al. A randomized, controlled study to investigate the analgesic efficacy of single doses of the cannabinoid receptor-2 agonist GW842166, ibuprofen or placebo in patients with acute pain following third molar tooth extraction. Clin J Pain. 2011;27(8):668\u201376.","journal-title":"Clin J Pain"},{"issue":"2","key":"1098_CR96","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1124\/mol.117.109355","volume":"93","author":"X Lin","year":"2018","unstructured":"Lin X, et al. Slowly signaling G protein-biased CB(2) cannabinoid receptor agonist LY2828360 suppresses neuropathic pain with sustained efficacy and attenuates morphine tolerance and dependence. Mol Pharmacol. 2018;93(2):49\u201362.","journal-title":"Mol Pharmacol"},{"key":"1098_CR97","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1146\/annurev-pharmtox-030220-112741","volume":"61","author":"N van Egmond","year":"2021","unstructured":"van Egmond N, Straub VM, van der Stelt M. Targeting endocannabinoid signaling: FAAH and MAG lipase inhibitors. Annu Rev Pharmacol Toxicol. 2021;61:441\u201363.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"12","key":"1098_CR98","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1093\/pm\/pnx046","volume":"18","author":"D Bradford","year":"2017","unstructured":"Bradford D, et al. The MOBILE study-a phase IIa enriched enrollment randomized withdrawal trial to assess the analgesic efficacy and safety of ASP8477, a fatty acid amide hydrolase inhibitor, in patients with peripheral neuropathic pain. Pain Med. 2017;18(12):2388\u2013400.","journal-title":"Pain Med"},{"key":"1098_CR99","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.urology.2017.02.029","volume":"103","author":"FME Wagenlehner","year":"2017","unstructured":"Wagenlehner FME, et al. Fatty acid amide hydrolase inhibitor treatment in men with chronic prostatitis\/chronic pelvic pain syndrome: an adaptive double-blind, randomized controlled trial. Urology. 2017;103:191\u20137.","journal-title":"Urology"},{"issue":"6","key":"1098_CR100","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s00345-020-03372-z","volume":"39","author":"JGA Houbiers","year":"2021","unstructured":"Houbiers JGA, et al. An adaptive randomized clinical trial in interstitial cystitis\/bladder pain syndrome evaluating efficacy of ASP3652 and the relationship between disease characteristics and Hunner\u2019s lesions. World J Urol. 2021;39(6):2065\u201371.","journal-title":"World J Urol"},{"key":"1098_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2020.173059","volume":"199","author":"DJ Sholler","year":"2020","unstructured":"Sholler DJ, et al. Therapeutic potential and safety considerations for the clinical use of synthetic cannabinoids. Pharmacol Biochem Behav. 2020;199: 173059.","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"1098_CR102","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.7326\/M21-4520","volume":"175","author":"MS McDonagh","year":"2022","unstructured":"McDonagh MS, et al. Cannabis-based products for chronic pain: a systematic review. Ann Intern Med. 2022;175(8):1143\u201353.","journal-title":"Ann Intern Med"},{"issue":"4","key":"1098_CR103","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1136\/rapm-2021-103431","volume":"48","author":"AL McParland","year":"2023","unstructured":"McParland AL, et al. Evaluating the impact of cannabinoids on sleep health and pain in patients with chronic neuropathic pain: a systematic review and meta-analysis of randomized controlled trials. Reg Anesth Pain Med. 2023;48(4):180\u201390.","journal-title":"Reg Anesth Pain Med"},{"issue":"3","key":"1098_CR104","first-page":"CD012182","volume":"3","author":"M Mucke","year":"2018","unstructured":"Mucke M, et al. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2018;3(3):CD012182.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5\u20136","key":"1098_CR105","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1159\/000481089","volume":"78","author":"S Schimrigk","year":"2017","unstructured":"Schimrigk S, et al. Dronabinol is a safe long-term treatment option for neuropathic pain patients. Eur Neurol. 2017;78(5\u20136):320\u20139.","journal-title":"Eur Neurol"},{"issue":"10","key":"1098_CR106","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/PHM.0b013e3181f1c4ec","volume":"89","author":"DH Rintala","year":"2010","unstructured":"Rintala DH, et al. Effect of dronabinol on central neuropathic pain after spinal cord injury: a pilot study. Am J Phys Med Rehabil. 2010;89(10):840\u20138.","journal-title":"Am J Phys Med Rehabil"},{"issue":"7460","key":"1098_CR107","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1136\/bmj.38149.566979.AE","volume":"329","author":"KB Svendsen","year":"2004","unstructured":"Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ. 2004;329(7460):253.","journal-title":"BMJ"},{"key":"1098_CR108","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2147\/JPR.S340968","volume":"15","author":"MA Ueberall","year":"2022","unstructured":"Ueberall MA, et al. Comparison of the effectiveness and tolerability of nabiximols (THC:CBD) oromucosal spray versus oral dronabinol (THC) as add-on treatment for severe neuropathic pain in real-world clinical practice: retrospective analysis of the German Pain e-Registry. J Pain Res. 2022;15:267\u201386.","journal-title":"J Pain Res"},{"issue":"7637","key":"1098_CR109","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1136\/bmj.39429.619653.80","volume":"336","author":"B Frank","year":"2008","unstructured":"Frank B, et al. Comparison of analgesic effects and patient tolerability of nabilone and dihydrocodeine for chronic neuropathic pain: randomised, crossover, double blind study. BMJ. 2008;336(7637):199\u2013201.","journal-title":"BMJ"},{"issue":"10","key":"1098_CR110","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/j.pain.2012.06.024","volume":"153","author":"C Toth","year":"2012","unstructured":"Toth C, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012;153(10):2073\u201382.","journal-title":"Pain"},{"issue":"4","key":"1098_CR111","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/j.1533-2500.2010.00427.x","volume":"11","author":"JA Bestard","year":"2011","unstructured":"Bestard JA, Toth CC. An open-label comparison of nabilone and gabapentin as adjuvant therapy or monotherapy in the management of neuropathic pain in patients with peripheral neuropathy. Pain Pract. 2011;11(4):353\u201368.","journal-title":"Pain Pract"},{"issue":"1","key":"1098_CR112","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/pme.12569","volume":"16","author":"D Turcotte","year":"2015","unstructured":"Turcotte D, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med. 2015;16(1):149\u201359.","journal-title":"Pain Med"},{"issue":"10","key":"1098_CR113","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1007\/s00415-006-0218-8","volume":"253","author":"J Wissel","year":"2006","unstructured":"Wissel J, et al. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol. 2006;253(10):1337\u201341.","journal-title":"J Neurol"},{"issue":"5","key":"1098_CR114","first-page":"CD013444","volume":"5","author":"G Filippini","year":"2022","unstructured":"Filippini G, et al. Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis. Cochrane Database Syst Rev. 2022;5(5):CD013444.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1098_CR115","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1213\/ANE.0b013e3181c76f70","volume":"110","author":"MA Ware","year":"2010","unstructured":"Ware MA, et al. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesth Analg. 2010;110(2):604\u201310.","journal-title":"Anesth Analg"},{"issue":"2","key":"1098_CR116","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jpain.2007.09.002","volume":"9","author":"RQ Skrabek","year":"2008","unstructured":"Skrabek RQ, et al. Nabilone for the treatment of pain in fibromyalgia. J Pain. 2008;9(2):164\u201373.","journal-title":"J Pain"},{"key":"1098_CR117","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.coph.2018.03.012","volume":"40","author":"M O'Brien","year":"2018","unstructured":"O\u2019Brien M, McDougall JJ. Cannabis and joints: scientific evidence for the alleviation of osteoarthritis pain by cannabinoids. Curr Opin Pharmacol. 2018;40:104\u20139.","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"1098_CR118","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1111\/bph.14204","volume":"176","author":"N Malek","year":"2019","unstructured":"Malek N, Starowicz K. Joint problems arising from lack of repair mechanisms: can cannabinoids help? Br J Pharmacol. 2019;176(10):1412\u201320.","journal-title":"Br J Pharmacol"},{"issue":"11\u201312","key":"1098_CR119","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00508-006-0611-4","volume":"118","author":"M Pinsger","year":"2006","unstructured":"Pinsger M, et al. Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain\u2014a randomized controlled trial. Wien Klin Wochenschr. 2006;118(11\u201312):327\u201335.","journal-title":"Wien Klin Wochenschr"},{"issue":"8","key":"1098_CR120","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s10194-012-0490-1","volume":"13","author":"LA Pini","year":"2012","unstructured":"Pini LA, et al. Nabilone for the treatment of medication overuse headache: results of a preliminary double-blind, active-controlled, randomized trial. J Headache Pain. 2012;13(8):677\u201384.","journal-title":"J Headache Pain"},{"key":"1098_CR121","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2147\/JPR.S166617","volume":"11","author":"E Mondello","year":"2018","unstructured":"Mondello E, et al. Cannabinoids and spinal cord stimulation for the treatment of failed back surgery syndrome refractory pain. J Pain Res. 2018;11:1761\u20137.","journal-title":"J Pain Res"},{"issue":"6","key":"1098_CR122","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1503\/cjs.001018","volume":"62","author":"K Madden","year":"2019","unstructured":"Madden K, et al. Cannabis for pain in orthopedics: a systematic review focusing on study methodology. Can J Surg. 2019;62(6):369\u201380.","journal-title":"Can J Surg"},{"issue":"1","key":"1098_CR123","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13018-021-02205-y","volume":"16","author":"BJ Vivace","year":"2021","unstructured":"Vivace BJ, et al. Cannabinoids and orthopedic surgery: a systematic review of therapeutic studies. J Orthop Surg Res. 2021;16(1):57.","journal-title":"J Orthop Surg Res"},{"issue":"5","key":"1098_CR124","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1213\/ANE.0000000000000877","volume":"121","author":"M Kleine-Brueggeney","year":"2015","unstructured":"Kleine-Brueggeney M, et al. Intravenous delta-9-tetrahydrocannabinol to prevent postoperative nausea and vomiting: a randomized controlled trial. Anesth Analg. 2015;121(5):1157\u201364.","journal-title":"Anesth Analg"},{"issue":"4","key":"1098_CR125","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s12630-017-0814-3","volume":"64","author":"DN Levin","year":"2017","unstructured":"Levin DN, et al. A randomized-controlled trial of nabilone for the prevention of acute postoperative nausea and vomiting in elective surgery. Can J Anaesth. 2017;64(4):385\u201395.","journal-title":"Can J Anaesth"},{"issue":"8","key":"1098_CR126","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/BF03022793","volume":"53","author":"P Beaulieu","year":"2006","unstructured":"Beaulieu P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Can J Anaesth. 2006;53(8):769\u201375.","journal-title":"Can J Anaesth"},{"issue":"6","key":"1098_CR127","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1097\/AOG.0000000000003850","volume":"135","author":"AC Colwill","year":"2020","unstructured":"Colwill AC, et al. Cannabinoids for pain control during medical abortion: a randomized controlled trial. Obstet Gynecol. 2020;135(6):1289\u201395.","journal-title":"Obstet Gynecol"},{"issue":"7","key":"1098_CR128","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047717","volume":"11","author":"A Noori","year":"2021","unstructured":"Noori A, et al. Opioid-sparing effects of medical cannabis or cannabinoids for chronic pain: a systematic review and meta-analysis of randomised and observational studies. BMJ Open. 2021;11(7): e047717.","journal-title":"BMJ Open"},{"issue":"1\u20132","key":"1098_CR129","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0304-3959(03)00163-5","volume":"105","author":"M Naef","year":"2003","unstructured":"Naef M, et al. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain. 2003;105(1\u20132):79\u201388.","journal-title":"Pain"},{"issue":"1\u20132","key":"1098_CR130","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejphar.2005.11.036","volume":"530","author":"JD Roberts","year":"2006","unstructured":"Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol. 2006;530(1\u20132):54\u20138.","journal-title":"Eur J Pharmacol"},{"issue":"11","key":"1098_CR131","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.1007\/s00213-019-05293-1","volume":"236","author":"S Babalonis","year":"2019","unstructured":"Babalonis S, et al. Cannabinoid modulation of opioid analgesia and subjective drug effects in healthy humans. Psychopharmacology. 2019;236(11):3341\u201352.","journal-title":"Psychopharmacology"},{"issue":"8","key":"1098_CR132","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1038\/s41386-021-01007-4","volume":"46","author":"KE Dunn","year":"2021","unstructured":"Dunn KE, et al. Within-subject, double-blinded, randomized, and placebo-controlled evaluation of the combined effects of the cannabinoid dronabinol and the opioid hydromorphone in a human laboratory pain model. Neuropsychopharmacology. 2021;46(8):1451\u20139.","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"1098_CR133","doi-asserted-by":"publisher","DOI":"10.1111\/adb.13317","volume":"28","author":"JP De Aquino","year":"2023","unstructured":"De Aquino JP, et al. Delta-9-tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: a within-subject, randomized, placebo-controlled laboratory study. Addict Biol. 2023;28(9): e13317.","journal-title":"Addict Biol"},{"issue":"3","key":"1098_CR134","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jpain.2007.10.018","volume":"9","author":"S Narang","year":"2008","unstructured":"Narang S, et al. Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain. 2008;9(3):254\u201364.","journal-title":"J Pain"},{"issue":"Suppl 1","key":"1098_CR135","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1097\/j.pain.0000000000002266","volume":"162","author":"S Haroutounian","year":"2021","unstructured":"Haroutounian S, et al. International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. Pain. 2021;162(Suppl 1):S117-s124.","journal-title":"Pain"},{"issue":"3","key":"1098_CR136","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/ijms22031001","volume":"22","author":"A Lago-Fernandez","year":"2021","unstructured":"Lago-Fernandez A, et al. Relevance of peroxisome proliferator activated receptors in multitarget paradigm associated with the endocannabinoid system. Int J Mol Sci. 2021;22(3):1001.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1098_CR137","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1155\/2014\/754693","volume":"19","author":"D Moulin","year":"2014","unstructured":"Moulin D, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328\u201335.","journal-title":"Pain Res Manag"},{"issue":"2","key":"1098_CR138","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1098_CR139","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/ejp.1297","volume":"22","author":"W Hauser","year":"2018","unstructured":"Hauser W, et al. European Pain Federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur J Pain. 2018;22(9):1547\u201364.","journal-title":"Eur J Pain"},{"issue":"3","key":"1098_CR140","first-page":"443","volume":"48","author":"CC Felder","year":"1995","unstructured":"Felder CC, et al. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol. 1995;48(3):443\u201350.","journal-title":"Mol Pharmacol"},{"issue":"21","key":"1098_CR141","doi-asserted-by":"publisher","first-page":"15894","DOI":"10.1074\/jbc.M608287200","volume":"282","author":"MP Neeper","year":"2007","unstructured":"Neeper MP, et al. Activation properties of heterologously expressed mammalian TRPV2: evidence for species dependence. J Biol Chem. 2007;282(21):15894\u2013902.","journal-title":"J Biol Chem"},{"issue":"3","key":"1098_CR142","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1124\/jpet.107.134809","volume":"325","author":"L De Petrocellis","year":"2008","unstructured":"De Petrocellis L, et al. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J Pharmacol Exp Ther. 2008;325(3):1007\u201315.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"1098_CR143","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1007\/s11481-012-9399-3","volume":"7","author":"AG Granja","year":"2012","unstructured":"Granja AG, et al. A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis. J Neuroimmune Pharmacol. 2012;7(4):1002\u201316.","journal-title":"J Neuroimmune Pharmacol"},{"issue":"2","key":"1098_CR144","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/dote.12479","volume":"30","author":"Z Malik","year":"2017","unstructured":"Malik Z, et al. Dronabinol increases pain threshold in patients with functional chest pain: a pilot double-blind placebo-controlled trial. Dis Esophagus. 2017;30(2):1\u20138.","journal-title":"Dis Esophagus"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01098-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-024-01098-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-024-01098-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T11:22:34Z","timestamp":1721301754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-024-01098-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,1]]},"references-count":144,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1098"],"URL":"https:\/\/doi.org\/10.1007\/s40263-024-01098-9","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,1]]},"assertion":[{"value":"26 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to assist with the preparation of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Anca Maglaviceanu and Drs. Miki Peer, Jason Rockel, Robert P. Bonin, Mary-Ann Fitzcharles, Karim S Ladha, Anuj Bhatia, Lakshmi Kotra, Mohit Kapoor, and Hance Clarke declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent Participation"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent Publication"}},{"value":"Anca Maglaviceanu, Miki Peer, and Hance Clarke contributed to the study conception and design, performed the literature searches, and wrote the first draft of the manuscript. All authors participated in the critical revision of the manuscript. All authors read and approved of the final manuscript and agree to be accountable for the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analysed during the current study.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}